Pharma industry hopes for drug-price delay dashed again: As the Trump administration pushes ahead with another round of IRA prescription drug-price negotiations, a delay seems unlikely.

The Ozempic shortage is over: We explore how an FDA decision impacts compounded weight loss drug sellers like Hims & Hers and patients who are prescribed GLP-1s.

It’s about to get a lot harder to get cheap GLP-1s: Rising costs may force consumers to cut back on discretionary spending, creating headwinds for retailers already fearing tariff-driven cost increases.

CMS unveils list of drugs for the next round of Medicare price negotiations: Drugmakers’ efforts to win over the Trump administration could amend the process in their favor—up to a certain point.

UPS pushes into healthcare logistics: The company is renting out custom lab space near its main global air hub. Diagnostics companies will be able to consolidate their shipping operations and drive downstream cost-savings.

Households with GLP-1 users slash their spending on groceries: Food companies need to adapt to the shifting buying patterns of consumers on GLP-1s to stay competitive.

US consumers see weight loss drugs as more effective than diet, exercise: Many plan to take a GLP-1 in 2025. Marketers in the health, wellness, and fitness spaces must pounce on the opportunity to frame their offerings as a better long-term bet than weight loss drugs.

Social media fuels micro-dosing trend with Ozempic: The trend speaks to the power of social health influencers, but emphasizes responsibility to marketers who need to make sure consumers are getting the most accurate drug information on the channel.

Eli Lilly and Ro join forces to offer lower price vials of Zepbound: Seeing competitors become business partners may seem surprising, but we detail why the deal makes sense for both parties.

Ozempic is becoming cheaper for Medicare beneficiaries: Falling prices are welcome news for seniors’ wallets. But a new proposal to expand access to GLP-1s for Medicare members could threaten the federal health insurance program itself.

Trump’s healthcare picks will look to rein in GLP-1 spending: His selections to run the FDA and HHS aren’t big proponents of widespread GLP-1 use for weight loss. We explore what it could mean for the obesity drug market amid a new administration.

Hims to offer a generic GLP-1 in 2025: It’s preparing for headwinds if the FDA halts compounded versions of weight loss drugs. But we think its diverse D2C offerings and strong subscriber growth should help insulate it financially.

Novo asks FDA to ban compounders from making GLP-1 copies: The drugmaker argues Ozempic’s key ingredient is too complex to make safely, even during shortages. With patient access to affordable GLP-1s on the line, the FDA has a difficult decision to make.

Bad actors flood the GLP-1 weight loss drug market: Until the cost of branded GLP-1s drops, illegal online pharmacies advertising falsified versions of the drugs will keep lingering.

Eli Lilly’s GLP-1 medication shortage ends: The host of players who offer compounded versions of the blockbuster drugs don’t have to worry—yet.

Elevance, doctors quarrel over volume of Ozempic prescriptions: The insurer doesn’t want to cover Ozempic to treat obesity. But are healthcare providers the ones to blame?

Kourtney Kardashian’s Lemme rolls out “GLP-1” weight loss supplement: The move is ingenious from a marketing perspective. But the brand could find itself in drugmakers’ crosshairs with already confusing marketing about the supplement’s key ingredient.

Both retailers used generative AI to improve employee productivity in Q2—Walmart leveraged the tech to improve its product catalog and Target used it to enhance in-store employee tools. Target’s curbside pickup service helped it grow digital comparable sales 8.7% YoY, while Walmart’s marketplace and sales of GLP-1 drugs contributed to its 4.2% comp sales growth YoY.

Nestlé targets GLP-1 users with line of nutritious frozen meals: The CPG company sees an opportunity to gain an early advantage as consumers shift to healthier options.

The Ozempic effect could have wide-ranging implications beyond the food industry—if it exists: Apparel makers, beauty brands, and airlines could capitalize as GLP-1 adoption grows, but only if users stick to the meds.